sFas (CD95) / FasL are hallmarks of apoptosis involvement in pathogenesis of HIV. We assess changes in soluble Fas /FasL, CD4 % and HIV-1 viral load in patients prior to the initiation of antiretroviral therapy (ART) and 6 months thereafter. A prospective longitudinal study on sixty consented HIV-1 positive adults. sFas and sFasL levels were measured by ELISA. CD4 cell counts and HIV-1 viralloads were measured using standard methods. Samples were analysed according to the manufacturers’ guidelines.There was a significant positive correlation between HIV-1 viral load and FasL at six months (M6) on treatment [r = +0.49, (0.03)]. There were no correlation between sFas/FasL and CD4 cell counts [ r = -33 (0.16), -31 (0.17) -23 (0.03) respectively]. The significant correlation between sFasL and HIV-1 viral load at six months of ART suggests that sFasL could be a signal biomarker for HIV-1 disease progression. We have shown in this study that high levels of sFasL depict high HIV-1 viral loads and advance state of the HIV disease. These biomarker should be investigated further in other settings.
| Published in | International Journal of Immunology (Volume 4, Issue 1) |
| DOI | 10.11648/j.iji.20160401.11 |
| Page(s) | 1-5 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2016. Published by Science Publishing Group |
sFasligands (CD95), Apoptosis, HIV, AICD, ART
| [1] | Yu-Ting Lin Chia-Hung Yen Heng-Li Chen Yi-Je et al, The serologic decoy receptor 3 (DcR3) levels are associated with slower disease progression in HIV-1/AIDS patient. Journal of the formosom medical association 2015, 114, 498-505. |
| [2] | UNAIDS. Report of global AIDS epidermic.2008, 2009. |
| [3] | Fluur C, De Milito A, Fry TJ, Vivar N, Eidsmo L, Atlas A, Federici C, Matarrese P, Logozzi M, Rajnavölgyi E, Mackall CL, Fais S, Chiodi F, Rethi B. Potential role for IL-7 in Fas-mediated T cell apoptosis during HIV infection. J Immunol. 2007 Apr 15; 178(8): 5340-50. |
| [4] | Rethi B, Vivar N, Sammicheli S, Fluur C, Ruffin N, Atlas A, Rajnavolgyi E, Chiodi F. Priming of T cells to Fas-mediated proliferative signals by interleukin-7. Blood. 2008 Aug 15; 112(4): 1195-204. Epub 2008 Apr 25. First shared authorship. |
| [5] | Vivar N, Thang PH, Atlas A, Chiodi F, Rethi B. Potential role of CD8+CD28- T lymphocytes in immune activation during HIV-1 infection. AIDS. 2008 May 31; 22(9): 1083-6. |
| [6] | Gray L, Newell ML, Thorne C, Peckham C, Levy J; European Collaborative Study. Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics. 2001; 108: 116-22. |
| [7] | Dickover RE, Dillon M, Gillette SG, Deveikis A, Keller M, Plaeger-Marshall S, et al. Rapid increases in load of human immunodeficiency virus correlate with early disease progression and loss of CD4 cells in vertically infected infants. J Infect Dis. 1994; 170: 1279-84. |
| [8] | Cohen JJ. Apoptosis: Physiologic cell death. J Lab Clin Med 1994; 124(6): 761-5. |
| [9] | De Rossi A, Masiero S, Giaquinto C, Ruga E, Comar M, Giacca M, et al. Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection. J Clin Invest. 1996; 97: 323-30. |
| [10] | Salvatori F, Masiero S, Giaquinto C, Wade CM, Brown AJ, Chieco-Bianchi L, et al. Evolution of human immunodeficiency virus type 1 in perinatally infected infants with rapid and slow progression to disease. J Virol. 1997; 71: 4694-706. |
| [11] | Kalish LA, McIntosh K, Read JS, Diaz C, Landesman SH, Pitt J, et al. Evaluation of human immunodeficiency virus (HIV) type 1 load, CD4 T cell level and clinical class as time-fixed and time-varying Markers of disease progression in HIV-1-infected children. J Infect Dis. 1999; 180: 1514-20. |
| [12] | Rich KC, Fowler MG, Mofenson LM, Abboud R, Pitt J, Diaz C, et al. Maternal and infant factors predicting disease progression in human immunodeficiency virus type 1-infected infants. Women and Infants Transmission Study Group. Pediatrics. 2000; 105: e8. |
| [13] | Goulder PJ, Jeena P, Tudor-Williams G, Burchett S. Pediatric HIV infection: correlates of protective immunity and global perspectives in prevention and management. Br Med Bull. 2001; 58: 89-108. |
| [14] | Yu-Ting Lin Chia-Hung Yen Heng-Li Chen Yi-Je et al, The serologic decoy receptor 3 (DcR3) levels are associated with slower disease progression in HIV-1/AIDS patient. Journal of the formosom medical association 2015, 114, 498-505. |
| [15] | Roederer M, Dubs JG, Anderson MT, RajuPA, Herzenberg LA,. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest. 1995; 95: 2061-6. |
| [16] | Casella CR, Rapport EL, Finkel TH. Vpu increases susceptibility of human immunodeficiency virus type 1-infected cells to fas killing. J Virol. 1999; 73: 92-100. |
| [17] | Samuelsson A, Broström C, van Dijk N, Sönnerborg A, Chiodi F. Apoptosis of CD4+ and CD19+ cells during human immunodeficiency virus type 1 infection - correlation with clinical progression, viral load, and loss of humoral immunity. Virology. 1997; 238: 180-8. |
| [18] | Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunology. 2000; 1: 469-74. |
| [19] | Koesters SA, Alimonti JB, Wachihi C, Matu L, Anzala O, Kimani J, et al. IL-7 Ralpha expression on CD4+ T lymphocytes decreases with HIV disease progression and inversely correlates with immune activation. Eur J Immunol. 2006; 36: 336-44. |
| [20] | Yamana K, Bilim V, Hara N, Kasahara T, Itoi T, and Maruyama R, et al. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br J Cancer 2005; 93: 544e51. |
| [21] | Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997; 278: 1447-50. |
| [22] | Finkel TH, Tudor-Williams G, Banda NK, Cotton MF Curiel T, Monks C, et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med1995; 1: 129-34. |
| [23] | Alimonti JB, Ball TB, and Fowke KR. Mechanisms of CD4+T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol 2003; 84: 1649-61. |
| [24] | Holm GH, Gabuzda D. Distinct Mechanisms of CD4+ and CD8+ T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions. J Virol2005; 79: 6299-311. |
| [25] | GM, Ikomey, MC, OkomoAssoumou, J,Atashili, M,Mesembe, et, al. Plasma Concentration of Soluble Fas receptors and ligands in relation to CD4+cell counts in HIV-1positive and negative patients in Yaounde Cameroon. BMC Res Notes. 2012; 5: 322. |
| [26] | Gougeon ML, Montagnier L. Apoptosis in AIDS.Science. 1993; 260(5112): 1269–1270. doi: 10.1126/science. 8098552. |
| [27] | Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. AIDS. 2003; 17(4): 541–545. doi: 10.1097/00002030-200303070-00009. |
| [28] | Post FA, Wood R, Maartens G. CD4 and total lymphocyte counts as predictors of HIV disease progression. QJM. 1996; 89(7): 505–508. doi: 10.1093/qjmed/89.7.505. |
APA Style
George Mondinde Ikomey, Atashili Julius, Graeme Brendon Jacobs, Martha Tongo Mesembe, Agnes Eyoh, et al. (2016). Fas Mediated(CD95L) Periferal T-cell Apotosis Marker in Monitoring HIV-1 Disease Progression in Adults in Yaoundé, Cameroon. International Journal of Immunology, 4(1), 1-5. https://doi.org/10.11648/j.iji.20160401.11
ACS Style
George Mondinde Ikomey; Atashili Julius; Graeme Brendon Jacobs; Martha Tongo Mesembe; Agnes Eyoh, et al. Fas Mediated(CD95L) Periferal T-cell Apotosis Marker in Monitoring HIV-1 Disease Progression in Adults in Yaoundé, Cameroon. Int. J. Immunol. 2016, 4(1), 1-5. doi: 10.11648/j.iji.20160401.11
AMA Style
George Mondinde Ikomey, Atashili Julius, Graeme Brendon Jacobs, Martha Tongo Mesembe, Agnes Eyoh, et al. Fas Mediated(CD95L) Periferal T-cell Apotosis Marker in Monitoring HIV-1 Disease Progression in Adults in Yaoundé, Cameroon. Int J Immunol. 2016;4(1):1-5. doi: 10.11648/j.iji.20160401.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.iji.20160401.11,
author = {George Mondinde Ikomey and Atashili Julius and Graeme Brendon Jacobs and Martha Tongo Mesembe and Agnes Eyoh and Emilia Lyonga and Okomo Assoumou Marie Claire},
title = {Fas Mediated(CD95L) Periferal T-cell Apotosis Marker in Monitoring HIV-1 Disease Progression in Adults in Yaoundé, Cameroon},
journal = {International Journal of Immunology},
volume = {4},
number = {1},
pages = {1-5},
doi = {10.11648/j.iji.20160401.11},
url = {https://doi.org/10.11648/j.iji.20160401.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.20160401.11},
abstract = {sFas (CD95) / FasL are hallmarks of apoptosis involvement in pathogenesis of HIV. We assess changes in soluble Fas /FasL, CD4 % and HIV-1 viral load in patients prior to the initiation of antiretroviral therapy (ART) and 6 months thereafter. A prospective longitudinal study on sixty consented HIV-1 positive adults. sFas and sFasL levels were measured by ELISA. CD4 cell counts and HIV-1 viralloads were measured using standard methods. Samples were analysed according to the manufacturers’ guidelines.There was a significant positive correlation between HIV-1 viral load and FasL at six months (M6) on treatment [r = +0.49, (0.03)]. There were no correlation between sFas/FasL and CD4 cell counts [ r = -33 (0.16), -31 (0.17) -23 (0.03) respectively]. The significant correlation between sFasL and HIV-1 viral load at six months of ART suggests that sFasL could be a signal biomarker for HIV-1 disease progression. We have shown in this study that high levels of sFasL depict high HIV-1 viral loads and advance state of the HIV disease. These biomarker should be investigated further in other settings.},
year = {2016}
}
TY - JOUR T1 - Fas Mediated(CD95L) Periferal T-cell Apotosis Marker in Monitoring HIV-1 Disease Progression in Adults in Yaoundé, Cameroon AU - George Mondinde Ikomey AU - Atashili Julius AU - Graeme Brendon Jacobs AU - Martha Tongo Mesembe AU - Agnes Eyoh AU - Emilia Lyonga AU - Okomo Assoumou Marie Claire Y1 - 2016/03/22 PY - 2016 N1 - https://doi.org/10.11648/j.iji.20160401.11 DO - 10.11648/j.iji.20160401.11 T2 - International Journal of Immunology JF - International Journal of Immunology JO - International Journal of Immunology SP - 1 EP - 5 PB - Science Publishing Group SN - 2329-1753 UR - https://doi.org/10.11648/j.iji.20160401.11 AB - sFas (CD95) / FasL are hallmarks of apoptosis involvement in pathogenesis of HIV. We assess changes in soluble Fas /FasL, CD4 % and HIV-1 viral load in patients prior to the initiation of antiretroviral therapy (ART) and 6 months thereafter. A prospective longitudinal study on sixty consented HIV-1 positive adults. sFas and sFasL levels were measured by ELISA. CD4 cell counts and HIV-1 viralloads were measured using standard methods. Samples were analysed according to the manufacturers’ guidelines.There was a significant positive correlation between HIV-1 viral load and FasL at six months (M6) on treatment [r = +0.49, (0.03)]. There were no correlation between sFas/FasL and CD4 cell counts [ r = -33 (0.16), -31 (0.17) -23 (0.03) respectively]. The significant correlation between sFasL and HIV-1 viral load at six months of ART suggests that sFasL could be a signal biomarker for HIV-1 disease progression. We have shown in this study that high levels of sFasL depict high HIV-1 viral loads and advance state of the HIV disease. These biomarker should be investigated further in other settings. VL - 4 IS - 1 ER -
Email: